Ionis Pharmaceuticals (IONS) Stock Statistics & Valuation Metrics

Ionis Pharmaceuticals has a market cap or net worth of $12.03B. The enterprise value is $10.26B.

Ionis Pharmaceuticals has 161,974,400 shares outstanding. The number of shares has decreased by -2.65% in one year.

Ionis Pharmaceuticals’s return on equity (ROE) is -0.77 and return on invested capital (ROIC) is -17.34%.

The current PE Ratio of Ionis Pharmaceuticals is ―. Ionis Pharmaceuticals’s PEG ratio is -0.61.

In the last 12 months, Ionis Pharmaceuticals had revenue of 705.14M and earned -453.90M in profits. Earnings per share was -3.04.

In the last 12 months, operating cash flow was -247.01M and capital expenditures -55.65M, giving a free cash flow of -302.66M billion.

Ionis Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Ionis Pharmaceuticals upcoming earnings date is Feb 25, 2026, Before Open (Confirmed).

Ionis Pharmaceuticals as a current ratio of 8.47, with Debt / Equity ratio of 324.60%

In the past 12 months, Ionis Pharmaceuticals has paid -6.17M in taxes.

Ionis Pharmaceuticals EV to EBITDA ratio is -18.10, with an EV/FCF ratio of -11.72.

Ionis Pharmaceuticals has $2.24B in cash and marketable securities with $2.01B in debt, giving a net cash position of $234.00M billion.

Gross margin is 98.78%, with operating margin of -67.37%, and net profit margin of -64.37%.

The average price target for Ionis Pharmaceuticals is $80.80, which is 11.43% higher than the current price. The consensus rating is Strong Buy